Pacific Biosciences Of Stock Analysis

PACB Stock  USD 3.17  0.21  6.21%   
Pacific Biosciences of is undervalued with Real Value of 5.79 and Target Price of 13.77. The main objective of Pacific Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Pacific Biosciences of is worth, separate from its market price. There are two main types of Pacific Biosciences' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Pacific Biosciences' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Pacific Biosciences' stock to identify patterns and trends that may indicate its future price movements.
The Pacific Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Pacific Biosciences is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Pacific Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Pacific Biosciences' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Pacific Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacific Biosciences has Price/Earnings (P/E) ratio of 197.88. The entity recorded a loss per share of 1.21. The firm had not issued any dividends in recent years. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. Pacific Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 728 people. To find out more about Pacific Biosciences of contact Christian MBA at 650 521 8000 or learn more at https://www.pacb.com.

Pacific Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Pacific Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Pacific Biosciences of or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Pacific Biosciences generated a negative expected return over the last 90 days
Pacific Biosciences has high historical volatility and very poor performance
Pacific Biosciences has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 200.52 M. Net Loss for the year was (306.74 M) with profit before overhead, payroll, taxes, and interest of 53.47 M.
Pacific Biosciences of currently holds about 834.34 M in cash with (266.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Pacific Biosciences has a frail financial position based on the latest SEC disclosures
Over 97.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Pacific Biosciences of California Given New 7.00 Price Target at The Goldman Sachs Group - Defense World

Pacific Biosciences Upcoming and Recent Events

Earnings reports are used by Pacific Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pacific Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
15th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Pacific Largest EPS Surprises

Earnings surprises can significantly impact Pacific Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-02-01
2017-12-31-0.2-0.180.0210 
2015-08-05
2015-06-30-0.14-0.16-0.0214 
2022-02-15
2021-12-31-0.28-0.31-0.0310 
View All Earnings Estimates

Pacific Biosciences Thematic Classifications

In addition to having Pacific Biosciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Measuring and Control Equipment Idea
Measuring and Control Equipment
USA Equities from Measuring and Control Equipment industry as classified by Fama & French
Aggressive Defence Idea
Aggressive Defence
Small capitalization, high growth potential companies

Pacific Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Pacific Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pacific Biosciences of backward and forwards among themselves. Pacific Biosciences' institutional investor refers to the entity that pools money to purchase Pacific Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Farallon Capital Management, L.l.c.2023-12-31
6.2 M
State Street Corporation2023-12-31
5.6 M
Geode Capital Management, Llc2023-12-31
5.5 M
Macquarie Group Ltd2023-12-31
M
Bank Of New York Mellon Corp2023-12-31
4.9 M
Fmr Inc2023-12-31
3.7 M
T. Rowe Price Associates, Inc.2023-12-31
3.6 M
Capital World Investors2023-12-31
3.4 M
Goldman Sachs Group Inc2023-12-31
3.2 M
Ark Investment Management Llc2023-12-31
34.5 M
Vanguard Group Inc2023-12-31
26.8 M
Note, although Pacific Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pacific Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 849.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pacific Biosciences's market, we take the total number of its shares issued and multiply it by Pacific Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Pacific Profitablity

Pacific Biosciences' profitability indicators refer to fundamental financial ratios that showcase Pacific Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Pacific Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Pacific Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Pacific Biosciences' profitability requires more research than a typical breakdown of Pacific Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (1.53) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.42) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.42.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.37)(0.39)
Return On Capital Employed(0.19)(0.20)
Return On Assets(0.18)(0.18)
Return On Equity(0.44)(0.46)

Management Efficiency

Pacific Biosciences has return on total asset (ROA) of (0.1092) % which means that it has lost $0.1092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4853) %, meaning that it created substantial loss on money invested by shareholders. Pacific Biosciences' management efficiency ratios could be used to measure how well Pacific Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of April 15, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.2. At present, Pacific Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Non Currrent Assets Other are projected to grow to (421.5 M).
Last ReportedProjected for Next Year
Book Value Per Share 2.77  2.90 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share(0.86)(0.90)
Enterprise Value Over EBITDA(11.67)(12.26)
Price Book Value Ratio 3.55  4.30 
Enterprise Value Multiple(11.67)(12.26)
Price Fair Value 3.55  4.30 
Enterprise Value2.2 B1.8 B
The analysis of Pacific Biosciences' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Pacific Biosciences' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Pacific Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.832

Technical Drivers

As of the 15th of April 2024, Pacific Biosciences holds the Risk Adjusted Performance of (0.14), coefficient of variation of (413.40), and Variance of 24.87. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacific Biosciences, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to break down thirteen technical drivers for Pacific Biosciences, which can be compared to its competitors. Please check Pacific Biosciences standard deviation, maximum drawdown, kurtosis, as well as the relationship between the information ratio and potential upside to decide if Pacific Biosciences is priced some-what accurately, providing market reflects its current price of 3.17 per share. Given that Pacific Biosciences has information ratio of (0.26), we recommend you to check out Pacific Biosciences's recent market performance to make sure the company can sustain itself at a future point.

Pacific Biosciences Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Pacific Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Pacific Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Pacific Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacific Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacific Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pacific Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Pacific Biosciences Predictive Daily Indicators

Pacific Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pacific Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Pacific Biosciences Corporate Filings

11th of April 2024
Other Reports
ViewVerify
F4
19th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
6th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
5th of March 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
29th of February 2024
Other Reports
ViewVerify
F4
26th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
21st of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
15th of February 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Pacific Biosciences Forecast Models

Pacific Biosciences' time-series forecasting models are one of many Pacific Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pacific Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Pacific Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Pacific Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pacific shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pacific Biosciences. By using and applying Pacific Stock analysis, traders can create a robust methodology for identifying Pacific entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(1.59)(1.67)
Operating Profit Margin(1.55)(1.63)
Net Loss(1.53)(1.61)
Gross Profit Margin 0.20  0.29 

Current Pacific Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pacific analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pacific analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
13.77Buy12Odds
Pacific Biosciences of current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Pacific analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Pacific stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Pacific Biosciences, talking to its executives and customers, or listening to Pacific conference calls.
Pacific Analyst Advice Details

Pacific Stock Analysis Indicators

Pacific Biosciences of stock analysis indicators help investors evaluate how Pacific Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pacific Biosciences shares will generate the highest return on investment. By understating and applying Pacific Biosciences stock analysis, traders can identify Pacific Biosciences position entry and exit signals to maximize returns.
Begin Period Cash Flow325.4 M
Long Term Debt892.2 M
Common Stock Shares Outstanding253.6 M
Total Stockholder Equity701.3 M
Tax Provision-10.7 M
Property Plant And Equipment Net69 M
Cash And Short Term Investments631.7 M
Cash180.2 M
Accounts Payable15.1 M
Net Debt753.7 M
50 Day M A4.711
Total Current Liabilities95 M
Other Operating Expenses510.9 M
Non Current Assets TotalB
Non Currrent Assets Other-443.7 M
Stock Based Compensation72.1 M
When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Pacific Biosciences information on this page should be used as a complementary analysis to other Pacific Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for Pacific Stock analysis

When running Pacific Biosciences' price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Is Pacific Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.21)
Revenue Per Share
0.791
Quarterly Revenue Growth
1.133
Return On Assets
(0.11)
Return On Equity
(0.49)
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.